Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study

The treatment of older patients with acute lymphoblastic leukemia (ALL) still represents an unmet medical need. Here we report the results of a chemoimmunotherapy approach combining vincristine/dexamethasone and epratuzumab, a humanized monoclonal therapeutic antibody against CD22, in patients over

[1]  J. Cayuela,et al.  Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. , 2014, Blood.

[2]  J. Radich,et al.  SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia , 2014, British journal of haematology.

[3]  P. Chevallier,et al.  BCR‐ABL1 molecular remission after 90Y‐epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B‐ALL: proof of principle , 2013, European journal of haematology.

[4]  N. Gökbuget.  How I treat older patients with ALL. , 2013, Blood.

[5]  Scott E. Smith,et al.  High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Kreuzer,et al.  Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. , 2012, Blood.

[7]  P. Chevallier,et al.  Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series. , 2012, Leukemia research.

[8]  Xiaomin Lu,et al.  Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2 , 2011 .

[9]  T. Habermann,et al.  Patients Enrolled in the Gimema Lal 0496 Protocol Presentation and Correlation with Response to Induction Treatment in Adult T-cell Acute Lymphoblastic Leukemia: Biologic Profile At , 2005 .

[10]  R. Foà,et al.  Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases , 2011, Leukemia & lymphoma.

[11]  J. Esteve,et al.  Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. , 2010, Blood.

[12]  P. Chevallier,et al.  Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases , 2009, Leukemia.

[13]  M. Borowitz,et al.  Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Leonard,et al.  Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma , 2004, Clinical Cancer Research.

[15]  F. Mandelli,et al.  Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period. , 1995, Leukemia.